Salix Pharmaceuticals Acquires Patent from Olon Relating to Amorphous Rifaximin

Salix Pharmaceuticals, Ltd.

today announced that as of May 30, 2013, it had purchased from Olon S.p.A. (formerly Solmag) a pending patent application claiming amorphous rifaximin and an issued patent that Olon recently acquired from Apotex Pharmachem, Inc. claiming amorphous rifaximin, together with related intellectual property rights. Additionally, Olon granted Salix the exclusive worldwide right under Olon's intellectual property rights to exploit amorphous rifaximin. About XIFAXAN® (rifaximin) 550 mg tablets Indication for XIFAXAN® 550 mg XIFAXAN 550 mg is a rifamycin antibacterial indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of